

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.

Consolidated Financial Results for the Three Months Ended June 30, 2025 (Under Japanese GAAP)



August 8, 2025

Name of listed company: SHIP HEALTHCARE HOLDINGS, INC.
 Shares listed on: Tokyo Stock Exchange
 Code: 3360 URL <https://www.shiphd.co.jp/en/>
 Representative: (Title) President (Name) Futoshi Ohashi
 Contact: (Title) Executive Vice President (Name) Hiroshi Yokoyama Tel.: +81-6-6369-0130
 Scheduled start date for dividend payments: -
 Supplementary briefing materials on results: Yes
 Briefing on quarterly results: None

(All figures are rounded down to the nearest million yen.)

1. Consolidated financial results for the three months ended June 30, 2025

(April 1, 2025 – June 30, 2025)

(1) Consolidated operating results (cumulative total)

(Percentages represent year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	(Million yen)	%	(Million yen)	%	(Million yen)	%	(Million yen)	%
Three months ended June 30, 2025	163,310	5.2	2,953	(15.8)	3,099	(31.0)	2,030	(34.1)
June 30, 2024	155,219	6.0	3,507	(8.7)	4,491	(3.4)	3,081	2.8

Note: Comprehensive income: Three months ended June 30, 2025: ¥ 2,367 million ((30.0)%)

Three months ended June 30, 2024: ¥ 3,381 million ((37.3)%)

	Net income per share	Diluted net income per share
	(Yen)	(Yen)
Three months ended June 30, 2025	21.54	-
June 30, 2024	32.66	-

Note:

1. Diluted net income per shares in the three months ended June 2025 are not stated because there are no outstanding potential shares.

2. Provisional accounting treatment related to corporate combinations have been conducted in second quarter ended March 2025. The consolidated financial results for the three months ended June 30, 2024 reflect the finalized provisional accounting treatment.

(2) Consolidated financial condition

	Total assets	Net assets	Equity capital ratio
As of	(Million yen)	(Million yen)	%
June 30, 2025	367,169	146,422	39.6
March 31, 2025	381,702	150,280	39.1

Reference: Equity: Three months ended June 30, 2025: ¥ 145,316 million; FY ended March 2025: ¥149,077 million

2. Dividends

	Annual dividends				Total
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	
	(Yen)	(Yen)	(Yen)	(Yen)	(Yen)
FY ended March 2025	—	0.00	—	58.00	58.00
FY ending March 2026	—	—	—	—	—
FY ending March 2026 (forecast)	—	0.00	—	60.00	60.00

Note: Revisions made in most recently announced dividend forecasts: None

3. Forecast of consolidated financial results for the fiscal year ending March 31, 2026
(April 1, 2025 – March 31, 2026)

(Percentages represent changes from the same quarter of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	(Million yen)	%	(Million yen)	%	(Million yen)	%	(Million yen)	%	(Yen)
Cumulative through second quarter	315,000	1.6	8,000	3.3	8,500	1.0	5,500	(0.7)	58.53
Full-year	700,000	3.2	26,000	4.9	26,500	1.8	15,500	2.5	165.29

Note: Revisions made in most recently announced forecasts of business performance: None

Notes

(1) Significant changes in the scope of consolidation during consolidated cumulative quarter: Yes

New inclusion: 1 company (Notes) , Elimination: 9 companies (Notes)

(Notes) Details are in the attached document Page 10 “Changes in the scope of consolidation or of application of equity method”

(2) Application of special accounting methods for preparation of quarterly consolidated financial statements None

(3) Changes made in accounting policies, accounting estimates, and/or restatements:

(i) Changes in accounting policies associated with changes in accounting standards, etc.: None

(ii) Any changes in accounting policies other than those under (i) above: None

(iii) Changes in accounting estimates: None

(iv) Restatements: None

(4) Number of shares issued and outstanding (common stocks)

(i) Number of shares issued and outstanding at the end of the period (including treasury share)	As of June 30, 2025	94,350,134 shares	As of March 31, 2025	101,669,400 shares
(ii) Number of treasury share at the end of the period	As of June 30, 2025	260,000 shares	As of March 31, 2025	7,319,266 shares
(iii) Average number of shares during the period (quarterly cumulative)	As of June 30, 2025	94,285,134 shares	As of June 30, 2024	94,350,225 shares

* Review of the attached quarterly consolidated financial statements by a Certified Public Accountant or an audit firm : None

* Information on appropriate use of financial forecasts and other special notes:

- The forecasts of financial results and other forward-looking statements provided herein are based on information available at the time this document was prepared, and certain assumptions considered reasonable. We don't intend to promise the achievement of them. Actual results may differ significantly from forecasts due to various factors. For assumptions underlying forecasts of financial results, notes on use of forecasts of financial results, and other related information, please refer to “Information on consolidated financial forecasts and other forward-looking statements” on page 3 of the Annexed Materials.

○ Index of attached materials

1.	Outlook of business results	2
(1)	Outlook of business results of consolidated cumulative quarter	2
(2)	Outlook of financial position of consolidated cumulative quarter	3
(3)	Information on consolidated financial forecasts and other forward-looking statements	3
2.	Quarterly consolidated financial statements and notes thereto	4
(1)	Quarterly consolidated balance sheet	4
(2)	Quarterly consolidated statement of income and consolidated statement of comprehensive income	6
(3)	Notes on quarterly consolidated financial statements	8
	(Notes on segment information, etc.)	8
	(Notes in the event of significant changes in the amount of shareholders' equity)	10
	(Notes on the going concern assumption)	10
	(Notes on statements of Cash Flows)	10
	(Changes in the scope of consolidation or of application of equity method)	10

1. Outlook of business results

(1) Outlook Description of business results of consolidated cumulative quarter

The Japanese economy during the first quarter of the current consolidated cumulative period, showed signs of a moderate recovery, supported by continuous improvements in employment and income environments. However, persistently high energy prices, a prolonged depreciation of the yen and rising inflation continued to weigh heavily on households and corporate activities, leaving the economic outlook uncertain.

Japanese healthcare industry to which the Group operates, various initiatives commenced in FY2024, including the 8th national medical plan, the 4th Phase Medical Cost Optimization Plan and reforms in doctors' work styles. In addition, revisions to incentives for the development of digital healthcare infrastructure have further accelerated the need to promote digital transformation in medical sites. There is a continued demand to build an efficient and high-quality medical care system.

In the Group business under such conditions, although the Group recorded a year-on-year decline in profit for the first quarter due to the back-loaded nature of project deliveries in the Total Pack Produce Business, performance overall remained in line with internal plans. Furthermore, this fiscal year marks the first year of the Group's Medium-term management plan "SHIP VISION 2030", guided by three key measures "Creating new business", "Reorganization and integration" and "Expansion of the field of growth" under the basic policy "Portfolio Management through the Optimization of Group Management Resources".

For the first quarter of the current consolidated cumulative period, the various factors noted above resulted in net sales of 163,310 million yen (up 5.2% YoY), operating profit of 2,953 million yen (down 15.8% YoY), ordinary profit of 3,099 million yen (down 31.0% YoY), and profit attributable to owners of the parent of 2,030 million yen (down 34.1% YoY).

The Company conducted provisional accounting treatment related to a corporate combination, which has now been finalized during the previous semi-annual consolidated accounting period. Accordingly, for comparisons and analysis with the previous consolidated cumulative quarter, the Company has used the revised figures reflecting this finalized treatment.

Business results by segment are summarized below.

(i) Total Pack Produce business

In Total Pack Produce business, revenue and profit declined YoY due to the projects schedule being more heavily weighted toward the second half than in any of the past five years whereas the progress toward the full-year plan remains steady.

As a result, this segment recorded net sales of 23,834 million yen (down 5.8% YoY) and segment profit (operating profit) of 466 million yen (down 57.6% YoY).

(ii) Medical Supply business

In Medical Supply business, steady operations continued at the SPD facility launched in the previous fiscal year, and a new SPD project involving a bundled contract with multiple hospitals under different management bodies was initiated.

As a result, this segment recorded net sales of 121,896 million yen (up 8.2% YoY) and segment profit (operating profit) of 1,178 million yen (up 21.7% YoY).

(iii) Lifecare business

In Lifecare business, operating cost increased driven by raising expenses related to maintaining service quality and responding to inflationary pressures. In the food provision service, rising food prices including rice affected the business.

As a result, this segment recorded net sales of 9,234 million yen (up 1.1% YoY) and segment profit (operating profit) of 415 million yen (down 33.0% YoY).

(iv) Dispensing Pharmacy business

In Dispensing Pharmacy business, the performance progressed steadily supported by efforts to improve operational efficiency through reorganization and integration.

As a result, this segment recorded net sales of 8,346 million yen (up 2.2% YoY) and segment profit (operating profit) of 928 million yen (up 16.9% YoY).

(2) Outlook of financial position on consolidated cumulative quarter under review

Assets at the end of the consolidated first quarter stood at 367,169 million yen, down 14,532 million yen from the end of the previous consolidated fiscal year. The primary reasons for this decline included decrease of 23,442 million yen in “notes, accounts receivable, and contract asset”, despite increases of 3,066 million yen in “cash and deposits”, 2,718 million yen in “merchandise and finished goods”, 2,212 million yen in “electronically recorded monetary claims – operating”.

Liabilities stood at 220,747 million yen, down 10,674 million yen from the end of the previous consolidated fiscal year. The primary reasons for this decline included decreases of 12,119 million yen in “notes and accounts payable – trade”, 4,728 million yen in “income taxes payable”, despite increase of 3,515 million yen in “electronically recorded obligations – operating”.

Net assets stood at 146,422 million yen, down 3,858 million yen from the end of the previous consolidated fiscal year. The primary reasons for this decrease included decrease of 5,472 million yen in “retained earnings” due to payment of dividends, despite increase of 2,030 million yen in “retained earnings” from profit attributable to owners of parent. As a result of all these factors, equity capital ratio at the end of the consolidated first quarter stood at 39.6% (up 0.5% from the end of the previous consolidated fiscal year)

(3) Information on consolidated financial forecasts and other forward-looking statements

In general, business performance matched financial forecasts made at the start of the period. The consolidated financial forecasts for the fiscal year remain unchanged from the forecasts announced on May 13, 2025.

2. Quarterly consolidated financial statements and notes thereto

(1) Quarterly consolidated balance sheet

(Unit: Million yen)

	As of March 31, 2025	As of June 30, 2025
Assets		
Current assets		
Cash and deposits	77,502	80,568
Notes, accounts receivable, and contract asset	135,517	112,074
Electronically recorded monetary claims – operating	6,236	8,449
Lease investment assets	2,508	2,481
Merchandise and finished goods	23,575	26,294
Work in process	3,363	4,102
Raw materials and supplies	1,920	2,017
Other	8,863	9,629
Allowance for doubtful accounts	(31)	(21)
Total current assets	259,457	245,596
Non-current assets		
Property, plant, and equipment		
Buildings and structures, net	21,529	21,292
Land	18,162	18,101
Real estate for rent, net	8,080	8,035
Other, net	11,187	11,015
Total property, plant, and equipment	58,960	58,445
Intangible assets		
Goodwill	7,414	7,354
Other	5,316	5,141
Total intangible assets	12,731	12,496
Investments and other assets		
Investment securities	29,381	30,216
Long-term loans receivable	10,351	10,152
Other	14,055	13,425
Allowance for doubtful accounts	(3,236)	(3,162)
Total investments and other assets	50,553	50,632
Total non-current assets	122,245	121,573
Total assets	381,702	367,169

	(Unit: Million yen)	
	As of March 31, 2025	As of June30, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	121,667	109,547
Electronically recorded obligations - operating	35,470	38,985
Short-term loans payable	698	1,290
Income taxes payable	5,932	1,203
Provision for bonuses	3,135	3,392
Other	21,109	23,359
Total current liabilities	188,013	177,779
Non-current liabilities		
Long-term loans payable	30,620	30,266
Net defined benefit liability	3,531	3,510
Asset retirement obligations	1,190	1,191
Other	8,064	8,000
Total non-current liabilities	43,408	42,968
Total liabilities	231,421	220,747
Net assets		
Shareholders' equity		
Capital stock	15,553	15,553
Capital surplus	23,575	19,418
Retained earnings	120,407	105,394
Treasury share	(15,527)	(549)
Total shareholders' equity	144,008	139,816
Accumulated other comprehensive income		
Valuation differences on available-for-sale securities	5,182	5,693
Deferred gains or losses on hedges	2	2
Foreign currency translation adjustments	(215)	(276)
Remeasurements of defined benefit plans	99	81
Total accumulated other comprehensive income	5,068	5,500
Non-controlling interests	1,203	1,106
Total net assets	150,280	146,422
Total liabilities and net assets	381,702	367,169

(2) Quarterly consolidated statement of income and consolidated statement of comprehensive income

Quarterly consolidated statement of income

Consolidated cumulative first quarter

(Unit: Million yen)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Net sales	155,219	163,310
Cost of sales	141,530	149,577
Gross profit	13,689	13,733
Sales, general, and administrative expenses	10,181	10,779
Operating profit	3,507	2,953
Non-operating profit		
Interest income	75	55
Dividend income	128	135
Equity gains of affiliated companies	652	144
Foreign exchange profit	170	-
Other	112	173
Total non-operating profit	1,139	508
Non-operating expenses		
Interest expenses	123	112
Commission paid	-	219
Other	32	30
Total non-operating expenses	156	362
Ordinary profit	4,491	3,099
Extraordinary profit		
Gains on sales of non-current assets	0	8
Gain on extinguishment of tie-in shares	-	3
Other	-	0
Total extraordinary profit	0	12
Extraordinary losses		
Loss on sales of non-current assets	2	0
Losses on retirement of non-current assets	1	18
Other	-	0
Total extraordinary losses	3	18
Profit before income taxes	4,488	3,094
Income taxes - current	1,150	1,073
Income taxes - deferred	315	44
Total income taxes	1,465	1,117
Profit	3,022	1,976
Losses attributable to non-controlling interests	(59)	(54)
Profit attributable to owners of parent	3,081	2,030

Quarterly consolidated statement of comprehensive income
Consolidated cumulative first quarter

	(Unit: Million yen)	
	Three months ended June 30, 2024	Three months ended June 30, 2025
Net income	3,022	1,976
Other comprehensive income		
Valuation differences on available-for-sale securities	381	507
Foreign currency translation adjustments	(16)	(91)
Remeasurements of defined benefit plans	(2)	(6)
Share of other comprehensive income of entities accounted for using equity method	(2)	(17)
Total other comprehensive income	359	391
Comprehensive income	3,381	2,367
(Breakdown)		
Comprehensive income attributable to owners of parent	3,450	2,461
Comprehensive income attributable to non-controlling interests	(68)	(94)

(3) Notes on consolidated quarterly financial statements

(Notes on Segment information, etc.)

I. Previous consolidated cumulative first quarter (April 1, 2024 – June 30, 2024)

1 Net sales and profit (loss) by reportable segments

(Unit: Million yen)

	Reportable segment					Adjustments*1	Amount recorded on consolidated financial statements*2
	Total Pack Produce business	Medical Supply business	Lifecare business	Dispensing Pharmacy business	Subtotal		
Net sales							
(1) Sales to outside customers	25,307	112,613	9,135	8,162	155,219	—	155,219
(2) Intersegment sales or transfers	545	588	12	27	1,175	(1,175)	—
Subtotal	25,852	113,202	9,148	8,190	156,394	(1,175)	155,219
Segment profit	1,098	968	620	793	3,481	26	3,507

Notes:

1. The figure of 26 million yen in adjustments to segment profit includes (31) million yen for the cancellation of intersegment transactions and 48 million yen for companywide costs not allocated to each reportable segment. These companywide costs consist mainly of parent company operating expenses and sales, general, and administrative expenses not attributable to individual reportable segments.
2. Segment profit is adjusted against the operating profit reported on the Quarterly consolidated statement of income.
3. The Company conducted provisional accounting treatment related to a corporate combination in the previous semi-annual consolidated accounting period. Accordingly, for segment information of the previous consolidated cumulative quarter, the Company has used the revised figures reflecting this finalized treatment.

2 Information on impairment loss and goodwill on fixed assets by reportable segments

No material impairment losses, changes in the amount of goodwill, and material gains on negative goodwill on fixed assets was recognized in the first quarter of the current consolidated fiscal year.

II Consolidated cumulative first quarter (April 1, 2025 – June 30, 2025)

1 Net sales and profit (loss) by reportable segments

(Unit: Million yen)

	Reportable segment					Adjustments*1	Amount recorded on consolidated financial statements*2
	Total Pack Produce business	Medical Supply business	Lifecare business	Dispensing Pharmacy business	Subtotal		
Net sales							
(1) Sales to outside customers	23,834	121,896	9,234	8,346	163,310	—	163,310
(2) Intersegment sales or transfers	436	409	26	31	904	(904)	—
Subtotal	24,271	122,306	9,260	8,377	164,215	(904)	163,310
Segment profit	466	1,178	415	928	2,989	(35)	2,953

Notes:

1. The figure of (35) million yen in adjustments to segment profit includes (14) million yen for the cancellation of intersegment transactions and (26) million yen for companywide costs not allocated to an individual reportable segment. These companywide costs consist mainly of parent company operating expenses and sales, general, and administrative expenses not attributable to individual reportable segments.

2. Segment profit is adjusted against the operating profit reported on the Quarterly consolidated statement of income.

2 Information on impairment loss and goodwill on fixed assets by reportable segments

No material impairment losses, changes in the amount of goodwill, and material gains on negative goodwill on fixed assets was recognized in the first quarter of the current consolidated fiscal year.

(Notes in the event of significant changes in the amount of shareholders' equity)

(Acquisition of treasury shares)

The Company acquired 260,000 treasury shares based on the resolution of its board of directors held on June 6, 2025. Accordingly, treasury share increased by 500 million yen.

(Cancellation of treasury shares)

The Company cancelled 7,319,266 treasury shares based on the resolution of its board of directors held on June 6, 2025. As a result, in the consolidated cumulative period of the first quarter, capital surplus and treasury stock each decreased by 15,477 million yen. Furthermore, due to cancellation of treasury shares, the balance of other capital surplus turned negative. Therefore, the other capital surplus was reduced to zero, and the negative amount was offset by a reduction from retained earnings brought forward.

(Notes on the going concern assumption)

None

(Notes on statements of Cash Flows)

The quarterly consolidated statement of cash flows for the first quarter of the consolidated cumulative period has not been prepared. However, depreciation and amortization of the period (including depreciation expense of intangible assets and excluding goodwill) and amortization of goodwill are below:

	Previous consolidated cumulative first quarter (April 1, 2024 – June 30, 2024)	Consolidated cumulative first quarter (April 1, 2025 – June 30, 2025)
Depreciation and amortization	1,353 million yen	1,311 million yen
Amortization of goodwill	455 million yen	406 million yen

(Changes in the scope of consolidation or of application of equity method)

(Changes in the scope of consolidation)

During the first quarter of this consolidated fiscal year, Tec International Inc. was newly included in the scope of consolidation by acquisition of its shares.

Kingrun Co., Ltd. absorbed and merged Kingrun Medicare Co., Ltd., Kingrun Kyushu Co., Ltd., Kingrun Hokkaido Co., Ltd. and Kingrun Kansai Co., Ltd., SHIP HEALTHCARE PHARMACY CO., LTD. (changed its name from SHIP HEALTHCARE PHARMACY EAST CO., LTD.) absorbed and merged Nisseichozai, Inc., GREEN PHARMACY Co., Ltd., STARSHIP Ltd., MONAKA CO., LTD. and OMP CO., LTD. (the latter two were non-consolidated subsidiaries in the last consolidated fiscal year), and SHIP HEALTHCARE FOOD, INC. absorbed and merged Grand-gourmet Co., Ltd.. All these transactions were organizational restructurings among consolidated subsidiaries.